Leukocyte chemoattractant receptors in human disease pathogenesis

Annual Review of Pathology: Mechanisms of Disease

Volumn 10, Issue , 2015, Pages 51-81

  Zabel, Brian A ^a   Rott, Alena ^a   Butcher, Eugene C ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

animal disease models; chemoattractant; chemokine; chemotaxis; GPCR; GWAS; homing; migration; polymorphisms; small molecule antagonists; trafficking

Indexed keywords

CHEMERIN; CHEMOATTRACTANT; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; DEFENSIN; LEUKOCYTE CHEMOATTRACTANT RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR;

ALLERGY; AMINO ACID SEQUENCE; ANCA ASSOCIATED VASCULITIS; ANGIOGENESIS; ARTICLE; ASTHMA; AUTOIMMUNE DISEASE; CHEMOTAXIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INFLAMMATORY DISEASE; LEUKOCYTE; LEUKOCYTE MIGRATION; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR INTERACTION; MULTIPLE SCLEROSIS; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; STEADY STATE; SUPPRESSOR CELL; UPREGULATION; ANIMAL; CELL MOTION; CYTOLOGY; DISEASE; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY;

ANIMALS; CELL MOVEMENT; CHEMOTAXIS, LEUKOCYTE; DISEASE; HUMANS; LEUKOCYTES; RECEPTORS, CELL SURFACE;

EID: 84921903612     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012513-104640     Document Type: Article

References (181)

1. Gowans JL, Knight EJ. 1964. The route of re-circulation of lymphocytes in the rat. Proc. R. Soc. B 159:257-82
2. Stamper HB Jr, Woodruff JJ. 1976. Lymphocyte homing into lymph nodes: in vitro demonstration of the selective affinity of recirculating lymphocytes for high-endothelial venules. J. Exp. Med. 144:828-33
3. Gallatin WM, Weissman IL, Butcher EC. 1983. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature 304:30-34
4. Butcher EC. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67:1033-36
5. Sanz MJ, Kubes P. 2012. Neutrophil-Active chemokines in in vivo imaging of neutrophil trafficking. Eur. J. Immunol. 42:278-83
6. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. 2007. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7:678-89
7. Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA, Butcher EC. 1998. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279:381-84
8. Lau EK, Allen S, Hsu AR, Handel TM. 2004. Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins. Adv. Protein Chem. 68:351-91
9. Salanga CL, Handel TM. 2011. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp. Cell Res. 317:590-601
10. Weber M, Hauschild R, Schwarz J, Moussion C, de Vries I, et al. 2013. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 339:328-32
11. Palanisamy V, Jakymiw A, Van Tubergen EA, D'Silva NJ, Kirkwood KL. 2012. Control of cytokine mRNA expression by RNA-binding proteins and microRNAs. J. Dent. Res. 91:651-58
12. Jenne CN, Urrutia R, Kubes P. 2013. Platelets: bridging hemostasis, inflammation, and immunity. Int. J. Lab. Hematol. 35:254-61
13. Du XY, Zabel BA, Myles T, Allen SJ, Handel TM, et al. 2009. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-Activable fibrinolysis inhibitor), and platelets. J. Biol. Chem. 284:751-58
14. Zabel BA, Kwitniewski M, Banas M, Zabieglo K, Murzyn K, Cichy J. 2014. Chemerin regulation and role in host defense. Am. J. Clin. Exp. Immunol. 3:1-19
15. Catalfamo M, Karpova T, McNally J, Costes SV, Lockett SJ, et al. 2004. Human CD8+ T cells store RANTES in a unique secretory compartment and release it rapidly after TcR stimulation. Immunity 20:219-30
16. Oynebraten I, Barois N, Hagelsteen K, Johansen FE, Bakke O, Haraldsen G. 2005. Characterization of a novel chemokine-containing storage granule in endothelial cells: evidence for preferential exocytosis mediated by protein kinase A and diacylglycerol. J. Immunol. 175:5358-69
17. Zabel BA, Zuniga L, Ohyama T, Allen SJ, Cichy J, et al. 2006. Chemoattractants, extracellular proteases, and the integrated host defense response. Exp. Hematol. 34:1021-32
18. Mortier A, Van Damme J, Proost P. 2012. Overview of the mechanisms regulating chemokine activity and availability. Immunol. Lett. 145:2-9
19. Proost P, Struyf S, VanDamme J. 2006. Natural post-Translationalmodifications of chemokines. Biochem. Soc. Trans. 34:997-1001
20. Mortier A, Van Damme J, Proost P. 2008. Regulation of chemokine activity by posttranslational modification. Pharmacol. Ther. 120:197-217
21. Wolf M, Albrecht S, Marki C. 2008. Proteolytic processing of chemokines: implications in physiological and pathological conditions. Int. J. Biochem. Cell Biol. 40:1185-98
22. Mortier A, Gouwy M, Van Damme J, Proost P. 2011. Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp. Cell Res. 317:642-54
23. Heutinck KM, ten Berge IJ, Hack CE, Hamann J, Rowshani AT. 2010. Serine proteases of the human immune system in health and disease. Mol. Immunol. 47:1943-55
24. Pham CT. 2006. Neutrophil serine proteases: specific regulators of inflammation. Nat. Rev. Immunol. 6:541-50
25. Miadonna A, Tedeschi A, Brasca C, Folco G, Sala A, Murphy RC. 1990. Mediator release after endobronchial antigen challenge in patients with respiratory allergy. J. Allergy Clin. Immunol. 85:906-13
26. Proudfoot AE. 2006. The biological relevance of chemokine-proteoglycan interactions. Biochem. Soc. Trans. 34:422-26
27. Proudfoot AE, Handel TM, Johnson Z, Lau EK, LiWang P, et al. 2003. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. USA 100:1885-90
28. Prossnitz ER, Gilbert TL, Chiang S, Campbell JJ, Qin S, et al. 1999. Multiple activation steps of the N-formyl peptide receptor. Biochemistry 38:2240-47
29. Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, et al. 2011. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477:549-55
30. Ulvmar MH, Hub E, Rot A. 2011. Atypical chemokine receptors. Exp. Cell Res. 317:556-68
31. Bamberg CE, Mackay CR, Lee H, Zahra D, Jackson J, et al. 2010. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J. Biol. Chem. 285:7633-44
32. Sanchez-Martin L, Sanchez-Mateos P, Cabanas C. 2013. CXCR7 impact on CXCL12 biology and disease. Trends Mol. Med. 19:12-22
33. Monnier J, Lewen S, O'Hara E, Huang K, Tu H, et al. 2012. Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells. J. Immunol. 189:956-67
34. Zabel BA, Nakae S, Zuniga L, Kim JY, Ohyama T, et al. 2008. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J. Exp. Med. 205:2207-20
35. Gonzalvo-Feo S, Del Prete A, Pruenster M, Salvi V, Wang L, et al. 2014. Endothelial cell-derived chemerin promotes dendritic cell transmigration. J. Immunol. 192:2366-73
36. Gether U. 2000. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21:90-113
37. Park SH, Das BB, Casagrande F, Tian Y, Nothnagel HJ, et al. 2012. Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 491:779-83
38. Wu B, Chien EY, Mol CD, Fenalti G, Liu W, et al. 2010. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:1066-71
39. Hanson MA, Roth CB, Jo E, Griffith MT, Scott FL, et al. 2012. Crystal structure of a lipid G protein-coupled receptor. Science 335:851-55
40. Venkatakrishnan AJ, Deupi X, Lebon G, Tate CG, Schertler GF, Babu MM. 2013. Molecular signatures of G-protein-coupled receptors. Nature 494:185-94
41. Monteclaro FS, Charo IF. 1996. The amino-Terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1αreceptor, confers chemokine selectivity: evidence for a two-step mechanism for MCP-1 receptor activation. J. Biol. Chem. 271:19084-92
42. Ludwig A, Ehlert JE, Flad HD, Brandt E. 2000. Identification of distinct surface-expressed and intracellular CXC-chemokine receptor 2 glycoforms in neutrophils: N-Glycosylation is essential for maintenance of receptor surface expression. J. Immunol. 165:1044-52
43. Broxmeyer HE, Kim CH. 1999. Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. Exp. Hematol. 27:1113-23
44. Ali H, Richardson RM, Haribabu B, Snyderman R. 1999. Chemoattractant receptor crossdesensitization. J. Biol. Chem. 274:6027-30
45. Lefkowitz RJ. 1998. G protein-coupled receptors. III. New roles for receptor kinases and β-Arrestins in receptor signaling and desensitization. J. Biol. Chem. 273:18677-80
46. Campbell JJ, Foxman EF, Butcher EC. 1997. Chemoattractant receptor cross talk as a regulatory mechanism in leukocyte adhesion and migration. Eur. J. Immunol. 27:2571-78
47. Foxman EF, Kunkel EJ, Butcher EC. 1999. Integrating conflicting chemotactic signals: the role of memory in leukocyte navigation. J. Cell Biol. 147:577-88
48. Foxman EF, Campbell JJ, Butcher EC. 1997. Multistep navigation and the combinatorial control of leukocyte chemotaxis. J. Cell Biol. 139:1349-60
49. McDonald B, Pittman K, Menezes GB, Hirota SA, Slaba I, et al. 2010. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 330:362-66
50. Lin F, Butcher EC. 2008. Modeling the role of homologous receptor desensitization in cell gradient sensing. J. Immunol. 181:8335-43
51. Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, et al. 2013. InternationalUnion of Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66:1-79
52. Schall TJ, Proudfoot AE. 2011. Overcoming hurdles in developing successful drugs targeting chemokine receptors. Nat. Rev. Immunol. 11:355-63
53. Horuk R. 2009. Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov. 8:23-33
54. Allegretti M, Cesta MC, Garin A, Proudfoot AE. 2012. Current status of chemokine receptor inhibitors in development. Immunol. Lett. 145:68-78
55. Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, et al. 2012. Pharmacological modulation of chemokine receptor function. Br. J. Pharmacol. 165:1617-43
56. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, et al. 1999. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur. Respir. J. 14:12-18
57. Anders HJ, Romagnani P, Mantovani A. 2014. Pathomechanisms: homeostatic chemokines in health, tissue regeneration, and progressive diseases. Trends Mol. Med. 20:154-65
58. Kunkel EJ, Butcher EC. 2002. Chemokines and the tissue-specific migration of lymphocytes. Immunity 16:1-4
59. Morteau O, Gerard C, Lu B, Ghiran S, Rits M, et al. 2008. An indispensable role for the chemokine receptor CCR10 in IgA antibody-secreting cell accumulation. J. Immunol. 181:6309-15
60. Cyster JG, Schwab SR. 2012. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol. 30:69-94
61. Golan K, Kollet O, Lapidot T. 2013. Dynamic cross talk between S1P andCXCL12regulates hematopoietic stem cells migration, development and bone remodeling. Pharmaceuticals 6:1145-69
62. Broxmeyer HE. 2008. Chemokines in hematopoiesis. Curr. Opin. Hematol. 15:49-58
63. Ratajczak MZ, Kim CH, Abdel-Latif A, Schneider G, Kucia M, et al. 2012. A novel perspective on stem cell homing andmobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients. Leukemia 26:63-72
64. Shi C, Jia T, Mendez-Ferrer S, Hohl TM, Serbina NV, et al. 2011. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating Toll-like receptor ligands. Immunity 34:590-601
65. Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, et al. 2005. Chemokine receptorCCR7required for T lymphocyte exit from peripheral tissues. Nat. Immunol. 6:889-94
66. Bromley SK, Thomas SY, Luster AD. 2005. Chemokine receptorCCR7guidesTcell exit from peripheral tissues and entry into afferent lymphatics. Nat. Immunol. 6:895-901
67. Teijeira A, Russo E, Halin C. 2014. Taking the lymphatic route: dendritic cell migration to draining lymph nodes. Semin. Immunopathol. 36:261-74
68. Kiefer F, Siekmann AF. 2011. The role of chemokines and their receptors in angiogenesis. Cell. Mol. Life Sci. 68:2811-30
69. Issa ME, Muruganandan S, Ernst MC, Parlee SD, Zabel BA, et al. 2012. Chemokine-like receptor 1 regulates skeletal muscle cell myogenesis. Am. J. Physiol. Cell Physiol. 302:C1621-31
70. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, et al. 2007. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J. Biol. Chem. 282:28175-88
71. Ernst MC, Haidl ID, Zuniga LA, Dranse HJ, Rourke JL, et al. 2012. Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance. Endocrinology 153:672-82
72. Metz-Boutigue MH, Shooshtarizadeh P, Prevost G, Haikel Y, Chich JF. 2010. Antimicrobial peptides present inmammalian skin and gut aremultifunctional defencemolecules. Curr. Pharm. Des. 16:1024-39
73. Kulig P, Kantyka T, Zabel BA, Banas M, Chyra A, et al. 2011. Regulation of chemerin chemoattractant and antibacterial activity by human cysteine cathepsins. J. Immunol. 187:1403-10
74. Banas M, Zabieglo K, Kasetty G, Kapinska-Mrowiecka M, Borowczyk J, et al. 2013. Chemerin is an antimicrobial agent in human epidermis. PLOS ONE 8:e58709
75. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, et al. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-77
76. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 273:1856-62
77. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, et al. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-25
78. Miller LH, Mason SJ, Clyde DF, McGinniss MH. 1976. The resistance factor to Plasmodium vivax in blacks-The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 295:302-4
79. Horuk R, Chitnis CE, Darbonne WC, Colby TJ, Rybicki A, et al. 1993. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 261:1182-84
80. Tournamille C, Colin Y, Cartron JP, Le Van Kim C. 1995. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nat. Genet. 10:224-28
81. Vergara C, Tsai YJ, Grant AV, Rafaels N, Gao L, et al. 2008. Gene encoding Duffy antigen/receptor for chemokines is associated with asthma and IgE in three populations. Am. J. Respir. Crit. Care Med. 178:1017-22
82. He W, Neil S, Kulkarni H, Wright E, Agan BK, et al. 2008. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 4:52-62
83. Hernandez PA, Gorlin RJ, Lukens JN, Taniuchi S, Bohinjec J, et al. 2003. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat. Genet. 34:70-74
84. Kallikourdis M, Trovato AE, Anselmi F, Sarukhan A, Roselli G, et al. 2013. The CXCR4 mutations in WHIM syndrome impair the stability of the T-cell immunologic synapse. Blood 122:666-73
85. Dale DC, Bolyard AA, Kelley ML, Westrup EC, Makaryan V, et al. 2011. The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome. Blood 118:4963-66
86. McDermott DH, Liu Q, Ulrick J, Kwatemaa N, Anaya-O'Brien S, et al. 2011. The CXCR4 antagonist plerixafor corrects panleukopenia in patients withWHIM syndrome. Blood 118:4957-62
87. MacGregor AJ, Snieder H, Rigby AS, Koskenvuo M, Kaprio J, et al. 2000. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43:30-47
88. Kurko J, Besenyei T, Laki J, Glant TT, Mikecz K, Szekanecz Z. 2013. Genetics of rheumatoid arthritis-A comprehensive review. Clin. Rev. Allergy Immunol. 45:170-79
89. Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, et al. 2010. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat. Genet. 42:515-19
90. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, et al. 2010. Genome-wide association study meta-Analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42:508-14
91. Jiang L, Yin J, Ye L, Yang J, Hemani G, et al. 2014. Novel risk loci for rheumatoid arthritis in Han Chinese and congruence with risk variants in Europeans. Arthritis Rheum. 66:1121-32
92. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, et al. 2008. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40:955-62
93. Quan C, Ren YQ, Xiang LH, Sun LD, Xu AE, et al. 2010. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat. Genet. 42:614-18
94. Yang SK, Hong M, Zhao W, Jung Y, Baek J, et al. 2014. Genome-wide association study of Crohn's disease in Koreans revealed three new susceptibility loci and common attributes of genetic susceptibility across ethnic populations. Gut 63:80-87
95. Lill CM, Schjeide BM, Graetz C, Ban M, Alcina A, et al. 2013. MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain 136:1778-82
96. Kemppinen AK, Kaprio J, Palotie A, Saarela J. 2011. Systematic review of genome-wide expression studies in multiple sclerosis. BMJ Open 1:e000053
97. Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, et al. 2011. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat. Genet. 43:329-32
98. Zhang J, Zhang Y, Yang J, Zhang L, Sun L, et al. 2014. Three SNPs in chromosome 11q23.3 are independently associated with systemic lupus erythematosus in Asians. Hum. Mol. Genet. 23:524-33
99. Lessard CJ, LiH, Adrianto I, Ice JA, Rasmussen A, et al. 2013. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome. Nat. Genet. 45:1284-92
100. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, et al. 2011. Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J. Natl. Cancer Inst. 103:817-25
101. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, et al. 2009. Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways. Nat. Genet. 41:199-204
102. Ellinghaus E, Ellinghaus D, Stuart PE, Nair RP, Debrus S, et al. 2010. Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. Nat. Genet. 42:991-95
103. Strange A, Capon F, Spencer CC, Knight J, Weale ME, et al. 2010. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat. Genet. 42:985-90
104. Huffmeier U, Uebe S, Ekici AB, Bowes J, Giardina E, et al. 2010. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat. Genet. 42:996-99
105. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, et al. 2012. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 44:1341-48
106. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, et al. 2012. Genetically distinct subsets within ANCA-Associated vasculitis. N. Engl. J. Med. 367:214-23
107. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, et al. 2013. Genome-wide association analysis identifies new susceptibility loci for Behcet's disease and epistasis betweenHLA-B 51 andERAP1. Nat. Genet. 45:202-7
108. Granada M, Wilk JB, Tuzova M, Strachan DP, Weidinger S, et al. 2012. A genome-wide association study of plasma total IgE concentrations in the Framingham Heart Study. J. Allergy Clin. Immunol. 129:840-45.e21
109. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, et al. 2009. Meta-Analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat. Genet. 41:776-82
110. Dubois PC, Trynka G, Franke L, Hunt KA, Romanos J, et al. 2010. Multiple common variants for celiac disease influencing immune gene expression. Nat. Genet. 42:295-302
111. Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, et al. 2008. Newly identified genetic risk variants for celiac disease related to the immune response. Nat. Genet. 40:395-402
112. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, et al. 2011. Meta-Analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat. Genet. 43:246-52
113. Heinig M, Petretto E, Wallace C, Bottolo L, Rotival M, et al. 2010. A trans-Acting locus regulates an anti-viral expression network and type 1 diabetes risk. Nature 467:460-64
114. Zeng Z, Shaffer JR, Wang X, Feingold E, Weeks DE, et al. 2013. Genome-wide association studies of pit-And-fissure-And smooth-surface caries in permanent dentition. J. Dent. Res. 92:432-37
115. Limou S, Coulonges C, Herbeck JT, van Manen D, An P, et al. 2010. Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-Term nonprogression to AIDS. J. Infect. Dis. 202:908-15
116. Raoul W, Auvynet C, Camelo S, Guillonneau X, Feumi C, et al. 2010. CCL2/CCR2 and CX3CL1/ CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J. Neuroinflamm. 7:87
117. Brion M, Sanchez-SalorioM, Corton M, de la FuenteM, Pazos B, et al. 2011. Genetic association study of age-related macular degeneration in the Spanish population. Acta Ophthalmol. 89:e12-22
118. Sadik CD, Luster AD. 2012. Lipid-cytokine-chemokine cascades orchestrate leukocyte recruitment in inflammation. J. Leukoc. Biol. 91:207-15
119. Islam SA, Luster AD. 2012. T cell homing to epithelial barriers in allergic disease. Nat. Med. 18:705-15
120. Murphy CT, Nally K, Shanahan F, Melgar S. 2012. Shining a light on intestinal traffic. Clin. Dev. Immunol. 2012:808157
121. Pelletier D, Hafler DA. 2012. Fingolimod for multiple sclerosis. N. Engl. J. Med. 366:339-47
122. Compston A, Coles A. 2008. Multiple sclerosis. Lancet 372:1502-17
123. Steinman L, Zamvil SS. 2005. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends Immunol. 26:565-71
124. Steinman L. 2001. Multiple sclerosis: a two-stage disease. Nat. Immunol. 2:762-64
125. Garin A, Proudfoot AE. 2011. Chemokines as targets for therapy. Exp. Cell Res. 317:602-12
126. Koelink PJ, Overbeek SA, Braber S, de Kruijf P, Folkerts G, et al. 2012. Targeting chemokine receptors in chronic inflammatory diseases: an extensive review. Pharmacol. Ther. 133:1-18
127. Lande R, Gafa V, Serafini B, Giacomini E, Visconti A, et al. 2008. Plasmacytoid dendritic cells in multiple sclerosis: intracerebral recruitment and impaired maturation in response to interferon-β. J. Neuropathol. Exp. Neurol. 67:388-401
128. Graham KL, Zabel BA, Loghavi S, Zuniga LA, Ho PP, et al. 2009. Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease. J. Immunol. 183:6717-23
129. Cruz-Orengo L, Holman DW, Dorsey D, Zhou L, Zhang P, et al. 2011. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J. Exp. Med. 208:327-39
130. Minten C, Alt C, Gentner M, Frei E, Deutsch U, et al. 2014. DARC shuttles inflammatory chemokines across the blood-brain barrier during autoimmune central nervous system inflammation. Brain 137:1454-69
131. Wang L, Du C, Lv J, WeiW, Cui Y, Xie X. 2011. Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 187:2336-45
132. Kihara Y, Yokomizo T, Kunita A, Morishita Y, Fukayama M, et al. 2010. The leukotriene B4 receptor, BLT1, is required for the induction of experimental autoimmune encephalomyelitis. Biochem. Biophys. Res. Commun. 394:673-78
133. Winer RA, Qin X, Harrington T, Moorman J, Zahran H. 2012. Asthma incidence among children and adults: findings from the Behavioral Risk Factor Surveillance System Asthma Call-Back Survey-United States, 2006-2008. J. Asthma 49:16-22
134. Galli SJ, Tsai M. 2012. IgE and mast cells in allergic disease. Nat. Med. 18:693-704
135. James JM, Crespo JF. 2007. Allergic reactions to foods by inhalation. Curr. Allergy Asthma Rep. 7:167-74
136. Nials AT, Uddin S. 2008. Mouse models of allergic asthma: acute and chronic allergen challenge. Dis. Models Mech. 1:213-20
137. Schmudde I, Laumonnier Y, Kohl J. 2013. Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. Semin. Immunol. 25:2-11
138. Medoff BD, Thomas SY, Luster AD. 2008. T cell trafficking in allergic asthma: the ins and outs. Annu. Rev. Immunol. 26:205-32
139. Mionnet C, Buatois V, Kanda A, Milcent V, Fleury S, et al. 2010. CX3CR1 is required for airway inflammation by promoting T helper cell survival andmaintenance in inflamed lung. Nat. Med. 16:1305-12
140. Honjo A, Ogawa H, Azuma M, Tezuka T, Sone S, et al. 2013. Targeted reduction of CCR4+ cells is sufficient to suppress allergic airway inflammation. Respir. Investig. 51:241-49
141. Matsunaga Y, Fukuyama S, Okuno T, Sasaki F, Matsunobu T, et al. 2013. Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia. FASEB J. 27:3306-14
142. Whitehead GS, Wang T, DeGraff LM, Card JW, Lira SA, et al. 2007. The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity.Am. J. Respir. Crit.CareMed. 175:243-49
143. Chen K, Le Y, Liu Y, GongW, Ying G, et al. 2010. A critical role for the G protein-coupled receptor mFPR2 in airway inflammation and immune responses. J. Immunol. 184:3331-35
144. Barrett NA, Rahman OM, Fernandez JM, Parsons MW, Xing W, et al. 2011. Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes. J. Exp. Med. 208:593-604
145. Otero K, Vecchi A, Hirsch E, Kearley J, Vermi W, et al. 2010. Nonredundant role of CCRL2 in lung dendritic cell trafficking. Blood 116:2942-49
146. Idzko M, Hammad H, van Nimwegen M, Kool M, Muller T, et al. 2006. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. J. Clin. Investig. 116:2935-44
147. Humbles AA, Lu B, Friend DS, Okinaga S, Lora J, et al. 2002. Themurine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness. Proc. Natl. Acad. Sci. USA 99:1479-84
148. Daubeuf F, Hachet-HaasM, Gizzi P, Gasparik V, Bonnet D, et al. 2013.Anantedrug of theCXCL12neutraligand blocks experimental allergic asthma without systemic effect in mice. J. Biol. Chem. 288:11865-76
149. Fregonese L, Silvestri M, Sabatini F, Rossi GA. 2002. Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin. Exp. Allergy 32:745-50
150. Wu AY, Chik SC, Chan AW, Li Z, Tsang KW, Li W. 2003. Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin. Exp. Allergy 33:359-66
151. Dyer KD, Percopo CM, Xie Z, Yang Z, Kim JD, et al. 2010. Mouse and human eosinophils degranulate in response to platelet-Activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor. J. Immunol. 184:6327-34
152. Mizutani N, Nabe T, Yoshino S. 2014. IL-17A promotes the exacerbation of IL-33-induced airway hyperresponsiveness by enhancing neutrophilic inflammation via CXCR2 signaling in mice. J. Immunol. 192:1372-84
153. Jones CP, Pitchford SC, Lloyd CM, Rankin SM. 2009. CXCR2 mediates the recruitment of endothelial progenitor cells during allergic airways remodeling. Stem Cells 27:3074-81
154. Cancer Research UK. 2014. Worldwide cancer key facts. Cancer Research UK, London. http://www. cancerresearchuk.org/cancer-info/cancerstats/keyfacts/worldwide/
155. Zlotnik A, Burkhardt AM, Homey B. 2011. Homeostatic chemokine receptors and organ-specificmetastasis. Nat. Rev. Immunol. 11:597-606
156. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. 2010. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328:749-52
157. Pachynski RK, Zabel BA, Kohrt HE, Tejeda NM, Monnier J, et al. 2012. The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. J. Exp. Med. 209:1427-35
158. Villablanca EJ, Raccosta L, Zhou D, Fontana R, Maggioni D, et al. 2010. Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 16:98-105
159. Gerber PA, Hippe A, Buhren BA, Muller A, Homey B. 2009. Chemokines in tumor-Associated angiogenesis. Biol. Chem. 390:1213-23
160. Muller A, Homey B, Soto H, Ge N, Catron D, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-56
161. Seo P, Stone JH. 2007. Small-vessel and medium-vessel vasculitis. Arthritis Rheum. 57:1552-59
162. Jennette JC, Xiao H, Falk R, Gasim AM. 2011. Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib. Nephrol. 169:211-20
163. Halbwachs L, Lesavre P. 2012. Endothelium-neutrophil interactions in ANCA-Associated diseases. J. Am. Soc. Nephrol. 23:1449-61
164. Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, et al. 2014. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J. Am. Soc. Nephrol. 25:225-31
165. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. 2009. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J. Am. Soc. Nephrol. 20:289-98
166. Yuan J, Gou SJ, Huang J, Hao J, Chen M, Zhao MH. 2012. C5a and its receptors in human antineutrophil cytoplasmic antibody (ANCA)-Associated vasculitis. Arthritis Res. Ther. 14:R140
167. Huugen D, van Esch A, Xiao H, Peutz-Kootstra CJ, Buurman WA, et al. 2007. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 71:646-54
168. Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. 2007. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am. J. Pathol. 170:52-64
169. van der Veen BS, Petersen AH, Belperio JA, Satchell SC, Mathieson PW, et al. 2009. Spatiotemporal expression of chemokines and chemokine receptors in experimental anti-myeloperoxidase antibody-mediated glomerulonephritis. Clin. Exp. Immunol. 158:143-53
170. Hao J, Wang C, Yuan J, Chen M, Zhao MH. 2013. A pro-inflammatory role of C5L2 in C5a-primed neutrophils for ANCA-induced activation. PLOS ONE 8:e66305
171. Kim SV, XiangWV, Kwak C, Yang Y, Lin XW, et al. 2013. GPR15-mediated homing controls immune homeostasis in the large intestine mucosa. Science 340:1456-59
172. Yonezawa T, Kurata R, Yoshida K, Murayama MA, Cui X, Hasegawa A. 2013. Free fatty acids-sensing G protein-coupled receptors in drug targeting and therapeutics. Curr. Med. Chem. 20:3855-71
173. Justus CR, DongL, Yang LV. 2013. Acidic tumormicroenvironment and pH-sensingGprotein-coupled receptors. Front. Physiol. 4:354
174. Barnea G, Strapps W, Herrada G, Berman Y, Ong J, et al. 2008. The genetic design of signaling cascades to record receptor activation. Proc. Natl. Acad. Sci. USA 105:64-69
175. Kang HK, Lee HY, Kim MK, Park KS, Park YM, et al. 2005. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met inhibits human monocyte-derived dendritic cell maturation via formyl peptide receptor and formyl peptide receptor-like 2. J. Immunol. 175:685-92
176. Migeotte I, Riboldi E, Franssen JD, Gregoire F, Loison C, et al. 2005. Identification and characterization of an endogenous chemotactic ligand specific for FPRL2. J. Exp. Med. 201:83-93
177. Vandenbroeck K. 2012. Cytokine gene polymorphisms and human autoimmune disease in the era of genome-wide association studies. J. Interf. Cytokine Res. 32:139-51
178. Guergnon J, Combadiere C. 2012. Role of chemokines polymorphisms in diseases. Immunol. Lett. 145:15-22
179. Poropatich K, Sullivan Jr. DJ. 2011. Human immunodeficiency virus type 1 long-Term non-progressors: the viral, genetic and immunological basis for disease non-progression. J. Gen. Virol. 92:247-68
180. Reiche EM, Bonametti AM, Voltarelli JC, Morimoto HK, Watanabe MA. 2007. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr. Med. Chem. 14:1325-34
181. Singh P, Kaur G, Sharma G, Mehra NK. 2008. Immunogenetic basis of HIV-1 infection, transmission and disease progression. Vaccine 26:2966-80